Recovery Peptides Anti-aging Mitochondrial Peptides Growth Factors Under research

Most-c

Also known as: MOST-C, MOST-C Peptide

MOST-C is a synthetic peptide derived from mitochondria, designed to mimic the action of the mitochondrial protein MOTS-c (mitochondrial open reading frame of the 12S rRNA-c). This peptide has been primarily investigated for its ability to improve mitochondrial function, promote cellular regeneration, and combat aging. It is believed to act as a mitochondrial growth factor, stimulating mitochondrial biogenesis and enhancing cellular energy efficiency. In preclinical studies, MOST-C has shown potential to increase physical endurance, reduce fatigue, improve insulin sensitivity, and promote repair of damaged tissues, especially in skeletal and cardiac muscle. It has also been explored for use in preventing metabolic and neurodegenerative diseases. However, its safety and efficacy profile in humans is not yet fully established, and its use is limited to scientific research.

Mechanism of action

MOST-C acts primarily as a mimetic of the MOTS-c protein, which is encoded by the mitochondrial gene MOTS-c. Its mechanism of action includes:

Stimulation of mitochondrial biogenesis: Activates pathways such as AMPK and PGC-1α, promoting the creation of new mitochondria.
Improvement of energy efficiency: Increases ATP production and reduces mitochondrial oxidative stress.
Metabolic regulation: Improves insulin sensitivity and glucose uptake in muscle cells.
Promotion of tissue regeneration: Stimulates stem cell proliferation and repair of damaged tissues.
Inflammation modulation: Reduces chronic inflammation associated with aging.

Uses & indications

Anti-aging: Investigated to delay cellular aging and improve longevity.
Physical performance enhancement: Potential to increase endurance and reduce muscle fatigue.
Muscle recovery: Aids in muscle tissue repair after injury or intense exercise.
Metabolic health: Possible use in treating insulin resistance and type 2 diabetes.
Cardiac protection: Studied to improve heart function and prevent cardiovascular diseases.

Effects

Reported effects in preclinical studies include increased physical endurance, improved insulin sensitivity, reduced body fat, increased lean muscle mass, improved mitochondrial function, and reduced oxidative stress. Improved recovery after muscle injuries and possible neuroprotection have also been observed.

Considerations & contraindications

MOST-C is a research-stage peptide and is not approved for human use by any regulatory agency. Complete data on its long-term safety, adverse effects, or drug interactions are not available. Possible adverse effects could include injection site reactions, metabolic alterations, or unknown long-term effects. Its use is not recommended outside controlled research settings. Contraindications: pregnancy, breastfeeding, pre-existing mitochondrial diseases, or active cancer.

Regulatory approval

MOST-C is not approved by the FDA, EMA, or any other regulatory agency for human use. It is only used in preclinical research and laboratory studies.

Dosage

No established doses for humans. In animal studies, doses of 1-5 mg/kg/day subcutaneously have been used. Not recommended for use without medical supervision.

Storage

Store lyophilized powder at -20°C. Once reconstituted, store at 2-8°C and use within 7 days. Protect from light and avoid freeze-thaw cycles.

Technical data

Regulatory status Under research

Molecular weight ~1500 Da

Half-life ~2-4 horas

Administration routes Subcutánea, intramuscular